Loading clinical trials...
Loading clinical trials...
Phase II, Randomized, Double-blinded, Placebo-Control, Toxicity/Efficacy Study on the Transfer of Adenovirus With the CD40 Ligand Gene (AdcuCD40L) to Patients With Stage I, II or III Esophageal Carcinoma
Conditions
Interventions
AdcuCD40L
Placebo
Start Date
July 1, 2011
Primary Completion Date
July 1, 2011
Completion Date
July 1, 2011
Last Updated
May 4, 2016
NCT07035587
NCT05688176
NCT05624099
NCT06027515
NCT06381583
NCT05680077
Lead Sponsor
Weill Medical College of Cornell University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions